Company overview
DEBRA Research, the research arm of DEBRA Austria, funds and advances translational research and clinical development for Epidermolysis Bullosa (EB) therapies. They build critical infrastructure including patient registries, biobanks, disease models, and clinical trial networks to accelerate EB treatment innovation. As a non-profit, they collaborate globally with academia, biotech, pharma, and patient organizations to turn research into curable solutions for EB.
DEBRA Research is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include debra research, epidermolysis bullosa, eb therapy development, eb clinical trials, rare disease research, patient registries.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.debra-research.org
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- debra research, epidermolysis bullosa, eb therapy development, eb clinical trials, rare disease research, patient registries, eb biobanks
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is DEBRA Research's primary focus?
- DEBRA Research focuses on translational research and clinical development to advance therapies and cures for Epidermolysis Bullosa (EB), a rare genetic skin disorder, through funding, infrastructure building, and global collaborations.
- What infrastructure capabilities do they provide for EB research?
- They develop essential EB research infrastructure such as patient registries, biobanks, preclinical models, disease atlases, and clinical trial networks to enable collaboration and accelerate therapy development.
- What are their geographic operations and partnerships?
- DEBRA Research operates worldwide from Munich, Germany, partnering with global entities including LEO Pharma (Denmark), Dermaliq, and UMC Groningen (Netherlands) for EB clinical trials and drug development.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
